Metacam Dosage Calculator for Cats

Metacam (active ingredient meloxicam) is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class, widely utilized across global veterinary medicine to treat pain, inflammation, and stiffness associated with acute soft tissue/orthopedic surgery and chronic osteoarthritis in felines.

Unlike classical non-selective NSAIDs such as aspirin or indomethacin, meloxicam functions as a preferential cyclooxygenase-2 (COX-2) inhibitor. This preferential selectivity blocks inflammatory prostanoids responsible for joint pain and fever while sparing, to a greater degree, the homeostatic COX-1 enzyme responsible for maintaining gastric mucosal blood flow and renal hemodynamics.

However, feline physiology presents a distinct pharmacogenomic challenge: cats have a natural genetic deficiency in multiple UDP-glucuronosyltransferase enzymes (notably UGT1A6 and UGT1A9), which drastically impairs their ability to perform glucuronide conjugation. As a result, meloxicam relies heavily on secondary oxidative pathways (cytochrome P450) and has an extended elimination half-life, necessitating meticulous dose calculation and cautious titration.

Meloxicam dosing follows strict weight-based pharmacokinetic protocols established by the International Society of Feline Medicine (ISFM) and veterinary regulatory agencies (such as the European Medicines Agency and Health Canada).

First, the patient body weight is converted to true metric kilograms: W_kg = W_lbs * 0.453592. Because obesity artificially inflates body weight with non-metabolizing adipose tissue, veterinarians often recommend calculating doses on lean or ideal body weight for overweight cats to prevent accidental toxicity.

Second, the required active ingredient mass is computed by multiplying the feline body mass by the target therapeutic dosage rate (Dose_mg = W_kg * Target_mg_per_kg). Standard protocols specify 0.10 mg/kg on Day 1 as an initial oral loading dose, followed by 0.05 mg/kg once daily for Days 2 to 4.

Third, the calculated active milligrams are converted into volumetric liquid units (mL) by dividing by the suspension concentration (Volume_mL = Dose_mg / Concentration_mg_per_mL). For standard feline 0.5 mg/mL suspension, a 4 kg cat at 0.05 mg/kg requires 0.20 mg, corresponding to exactly 0.40 mL.

Finally, for chronic management of degenerative joint disease, the ISFM consensus recommendations advise titrating the dose downward to the lowest effective maintenance level (often 0.015 to 0.03 mg/kg daily or every 48 hours) to preserve long-term renal and gastrointestinal safety.

Prescription Dose Volume (mL): The primary volumetric measurement to draw into your dosing syringe. This is the exact quantity you administer to your feline.

Total Active Drug (mg): The absolute amount of pure meloxicam molecule delivered per dose. Feline doses are tiny, often between 0.05 mg and 0.40 mg.

Target Dosage Rate (mg/kg): The relative clinical potency of the regimen. Standard daily maintenance is 0.05 mg/kg; chronic titrated therapy typically ranges from 0.015 to 0.03 mg/kg.

Suspension Strength: Highlights whether you are measuring 0.5 mg/mL (feline) or 1.5 mg/mL (canine) formulation, reinforcing the safety checks required to prevent dilution errors.

Safety Assessment Badge: Categorizes the regimen into Normal Feline Therapeutic Range, Elevated Initial Dose, Concentration Caution, or High-Dose Warning based on veterinary toxicology thresholds.

• Renal Health & Hydration Status: Prostaglandins generated by COX enzymes maintain renal perfusion during periods of reduced blood pressure. If a cat is dehydrated or has pre-existing subclinical chronic kidney disease (CKD), NSAID administration can precipitate acute renal decompensation.
• Deficient Feline Hepatic Glucuronidation: Cats lack functional UDP-glucuronosyltransferase UGT1A6. While dogs clear meloxicam relatively quickly, felines rely almost exclusively on fecal excretion and CYP450 oxidation, extending drug retention and elevating accumulation risk upon repeated daily dosing.
• Body Condition Score & Lean Mass: Adipose tissue does not clear NSAIDs; administering a full weight-based dose to an obese cat (BCS 8/9 or 9/9) effectively overdoses the animal. Lean or ideal body weight must be used for dosage calculations.
• Concurrent Pharmacotherapy: Meloxicam must NEVER be co-administered with corticosteroids (such as prednisolone or dexamethasone) or other NSAIDs due to extreme risk of gastrointestinal ulceration and perforation. Concomitant use with ACE inhibitors (benazepril) or diuretics (furosemide) warrants close renal monitoring.
• Formulation Discrepancies: Using canine Metacam (1.5 mg/mL) instead of feline Metacam (0.5 mg/mL) without adjusting volume results in an immediate 300% overdose. When using 1.5 mg/mL, a 0.3 mL or 0.5 mL micro-syringe is strictly required.

• Chronic Feline Osteoarthritis Management: Helping senior cats suffering from chronic joint pain regain mobility, jumping ability, and grooming behaviors under a titrated lowest-effective-dose protocol.
• Post-Surgical Analgesic Follow-Up: Calculating safe 1-to-4 day recovery dosages following routine spays, neuters, dental extractions, or soft tissue surgeries.
• Verification of Home Prescriptions: Double-checking veterinary liquid dispensing volumes before administering medication to prevent catastrophic home dosing errors.
• Titrating Down to Renal-Sparing Doses: Adjusting volumetric doses when shifting a stable arthritic cat from daily administration to alternate-day (q48h) micro-dosing.

• Assumes the cat is well-hydrated, actively eating, and has undergone baseline biochemical screening (BUN, creatinine, SDMA, and urinalysis).
• In the United States, the FDA approved feline Meloxicam solely as a single-dose subcutaneous injection for surgical pain, carrying a boxed warning against repeated oral use. However, outside the US (UK, Europe, Canada, Australia) and under ISFM international expert consensus, oral meloxicam is approved and widely practiced for long-term chronic feline pain.
• This tool is intended for educational and verification purposes and does not substitute for individualized veterinary diagnosis and ongoing clinical monitoring.